Dateline City:
KENILWORTH, N.J.
Data at ASCO Evaluates KEYTRUDA As Single Agent and in Novel Combinations in More Than 15 Different Cancers, Including Several New Tumors
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that new and updated data investigating KEYTRUDA
(pembrolizumab), the companys anti-PD-1 therapy, in more than 15 types
of cancer will be presented at the 52nd Annual Meeting of the
American Society of Clinical Oncology (ASCO) in Chicago, June 3 7,
2016.
Language:
English
Contact:
MerckMedia:Pamela Eisele, (267) 305-3558Kim Hamilton, (908) 740-1863orInvestor:Teri Loxam, (908) 740-1986Justin Holko, (908) 740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more